Chronic and recurrent non-infectious paediatric-onset uveitis: a French cohort.


Journal

RMD open
ISSN: 2056-5933
Titre abrégé: RMD Open
Pays: England
ID NLM: 101662038

Informations de publication

Date de publication:
2019
Historique:
received: 25 02 2019
revised: 17 06 2019
accepted: 23 06 2019
entrez: 28 8 2019
pubmed: 28 8 2019
medline: 28 8 2019
Statut: epublish

Résumé

To evaluate the demographics, aetiologies, complications, treatments and visual prognoses of chronic and recurrent non-infectious paediatric-onset uveitis in France. Descriptive, retrospective and bicentric study in patients whose disease started before 17 and who were followed up in two centres from January 2010 to May 2017. We included 147 patients with 268 affected eyes. Eighty-two had juvenile idiopathic arthritis-associated chronic uveitis, 58 were antinuclear antibody (ANA) positive and 24 were ANA negative, 36 had idiopathic uveitis, 9 had enthesitis-related arthritis-associated uveitis, 9 had sarcoidosis-associated uveitis and 11 had other inflammatory aetiologies. These patients cumulated 161 complications: ocular hypertension, cataract, band keratopathy, macular oedema, optic disk oedema and decreased visual acuity, including permanent visual loss for 31 patients. The most used treatments were corticosteroid (CS) eye drops (82%), systemic CSs (34%), methotrexate (58%) and biologics (38%). At the latest follow-up, 45 patients had achieved remission of uveitis without any treatment, 56 had inactive uveitis on topical steroids and 48 still had active uveitis. Paediatric-onset uveitis are associated with a high rate of complications. However, following the introduction of biologics and particularly antitumour necrosis factor alpha antibodies, a significant proportion of uveitis became inactive on or even off treatment.

Identifiants

pubmed: 31452929
doi: 10.1136/rmdopen-2019-000933
pii: rmdopen-2019-000933
pmc: PMC6691513
doi:

Substances chimiques

Adrenal Cortex Hormones 0
Antibodies, Antinuclear 0
Biological Factors 0
Immunosuppressive Agents 0
Methotrexate YL5FZ2Y5U1

Types de publication

Journal Article Observational Study

Langues

eng

Pagination

e000933

Déclaration de conflit d'intérêts

Competing interests: None.

Références

J Pediatr. 2017 Jul;186:131-137.e1
pubmed: 28457525
Ocul Immunol Inflamm. 2018;26(3):477-484
pubmed: 27775458
J Rheumatol. 2005 Feb;32(2):362-5
pubmed: 15693100
Ocul Immunol Inflamm. 2001 Dec;9(4):243-51
pubmed: 11935434
Joint Bone Spine. 2009 Jul;76(4):383-8
pubmed: 19524473
Pediatr Rheumatol Online J. 2018 Jul 11;16(1):46
pubmed: 29996864
Am J Ophthalmol. 2007 May;143(5):840-846
pubmed: 17362866
Semin Arthritis Rheum. 2011 Dec;41(3):503-10
pubmed: 21862108
Br J Ophthalmol. 1996 Apr;80(4):332-6
pubmed: 8703885
Clin Exp Rheumatol. 2013 Jul-Aug;31(4):633-7
pubmed: 23432940
Br J Ophthalmol. 2003 Jul;87(7):879-84
pubmed: 12812891
Br J Ophthalmol. 2007 Mar;91(3):319-24
pubmed: 17035274
Pediatr Rheumatol Online J. 2016 Apr 27;14(1):27
pubmed: 27121190
JAMA Ophthalmol. 2017 Jun 1;135(6):511-518
pubmed: 28426849
Pediatr Rheumatol Online J. 2018 Aug 6;16(1):51
pubmed: 30081917
Am J Ophthalmol. 2005 Sep;140(3):509-16
pubmed: 16196117
Br J Ophthalmol. 2005 Apr;89(4):444-8
pubmed: 15774921
Am J Ophthalmol. 2017 May;177:139-143
pubmed: 28257832
Best Pract Res Clin Rheumatol. 2016 Apr;30(2):304-315
pubmed: 27886802
Ophthalmology. 2004 Mar;111(3):491-500; discussion 500
pubmed: 15019324
Acta Ophthalmol Scand. 2000 Oct;78(5):576-9
pubmed: 11037918
Acta Paediatr. 2000 Aug;89(8):955-8
pubmed: 10976838
J Glaucoma. 2004 Apr;13(2):96-9
pubmed: 15097253
N Engl J Med. 2017 Apr 27;376(17):1637-1646
pubmed: 28445659
Stud Health Technol Inform. 2008;136:51-6
pubmed: 18487707
Ocul Immunol Inflamm. 2009 Jul-Aug;17(4):238-42
pubmed: 19657976
Ophthalmology. 2005 Jul;112(7):1287-92
pubmed: 15921752
Ocul Immunol Inflamm. 2018;26(4):584-594
pubmed: 28112975
Ophthalmology. 2015 Oct;122(10):1987-2001
pubmed: 26233626
Ophthalmology. 2009 Aug;116(8):1544-51, 1551.e1
pubmed: 19651312
JAMA Ophthalmol. 2013 Nov;131(11):1405-12
pubmed: 24008391
Am J Ophthalmol. 2003 May;135(5):676-80
pubmed: 12719076
F1000Prime Rep. 2014 Jun 02;6:41
pubmed: 24991418
J Rheumatol. 2007 May;34(5):1139-45
pubmed: 17343317
Rev Med Interne. 2003 Dec;24(12):794-802
pubmed: 14656639
Ocul Immunol Inflamm. 2006 Jun;14(3):145-50
pubmed: 16766397
Ann Rheum Dis. 2018 Jul;77(7):1003-1011
pubmed: 29275333
N Engl J Med. 2016 Sep 8;375(10):932-43
pubmed: 27602665

Auteurs

Guillaume Morelle (G)

RAISE reference centre for rare diseases, IMAGINE Institute, Immunologie, Hématologie et Rhumatologie Pédiatrique, Hopital universitaire Necker-Enfants malades, Assistance Publique Hopitaux de Paris, Paris, France.
Paris-Descartes University, Paris, France.

Julie Gueudry (J)

Ophthalmology Department, Centre Hospitalier Universitaire de Rouen, Rouen, France.

Florence Uettwiller (F)

Pediatric Department, CHRU Tours, Tours, France.

Carine Wouters (C)

RAISE reference centre for rare diseases, IMAGINE Institute, Immunologie, Hématologie et Rhumatologie Pédiatrique, Hopital universitaire Necker-Enfants malades, Assistance Publique Hopitaux de Paris, Paris, France.
Paris-Descartes University, Paris, France.
Pediatric Department, CHRU Tours, Tours, France.

Brigitte Bader-Meunier (B)

RAISE reference centre for rare diseases, IMAGINE Institute, Immunologie, Hématologie et Rhumatologie Pédiatrique, Hopital universitaire Necker-Enfants malades, Assistance Publique Hopitaux de Paris, Paris, France.
Paris-Descartes University, Paris, France.

Mathieu P Robert (MP)

Paris-Descartes University, Paris, France.
Ophthalmology Department, Hopital universitaire Necker-Enfants malades, Assistance Publique Hopitaux de Paris, Paris, France.
COGNAC-G, UMR 8257, CNRS-SSA, Universite Paris Descartes, Paris, France.

Dominique Monnet (D)

Paris-Descartes University, Paris, France.
Ophthalmology Department, Hopital Cochin, Assistance Publique Hopitaux de Paris, Paris, France.

Bahram Bodaghi (B)

Ophthalmology Department, Reference Center in Rare Diseases, Hopitaux Universitaires Pitie Salpetriere-Charles Foix, Assistance Publique Hopitaux de Paris, Paris, France.

Martine Grall-Lerosey (M)

Pediatrics Department, Centre Hospitalier Universitaire de Rouen, Rouen, France.

Pierre Quartier (P)

RAISE reference centre for rare diseases, IMAGINE Institute, Immunologie, Hématologie et Rhumatologie Pédiatrique, Hopital universitaire Necker-Enfants malades, Assistance Publique Hopitaux de Paris, Paris, France.
Paris-Descartes University, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH